Insight

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

Elisa Agostinetto/X

Jan 5, 2025, 18:21

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on LinkedIn:

“What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors (PPI) in breast cancer?

Can PPI use explain why the PALLAS trial was negative?

Now out in ESMO our analysis of PALLAS exploring this question.”

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Authors: E. Agostinetto, G. Pfeiler, D. Hlauschek, E.L. Mayer, M. Lambertini, E. de Azambuja, M. Bellet-Ezquerra, J.L. Meisel, G. Rubovszky, N. Zdenkowski, Y. Novik, M. Ruiz-Borrego, K.A. Gelmon, E.P. Mamounas, H. Iwata, D.R. Lu, L. Soelkner, C. Fesl, M. Gnant, A. DeMichele

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

A DeMichele Breast Cancer C. Fesl cancer D. Hlauschek D.R. Lu E. Agostinetto E. de Azambuja E.L. Mayer E.P. Mamounas Elisa Agostinetto G. Pfeiler G. Rubovszky H. Iwata J.L. Meisel K.A. Gelmon L. Soelkner M. Bellet-Ezquerra M. Gnant M. Lambertini M. Ruiz-Borrego N. Zdenkowski OncoDaily Oncology palbociclib PALLAS trial Y. Novik

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute